Overview

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Status:
RECRUITING

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.

Phase:

PHASE2

Details

Lead Sponsor:

Barbara Ann Karmanos Cancer Institute

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Taxes